Mechanism-aligned ketamine therapy for treatment-resistant depression: a 2026 update—toward an integrative mechanistic framework for clinical translation
Frontiers in Psychiatry · 20.11.2026 · 17
DOI: 10.3389/fpsyt.2026.1966279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 20.11.2026. Verfasst von Sherry-Anne Muscat und 1 weiteren Autor:innen. Die Arbeit nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Ketamine is increasingly understood to exert therapeutic effects through multiple interacting biological and experiential processes rather than a single pharmacological mechanism. In treatment-resistant depression (TRD), where conventional monoaminergic antidepressants often fail, ketamine’s rapid effects are thought to emerge through the coordinated, temporally structured engagement of five interacting domains: NMDAR modulation, neuroplastogenic processes, anti-inflammatory signaling, entropic brain state modulation, and psychedelic/mystical phenomenology. Building on the previously proposed systems-level model, this narrative review integrates foundational mechanistic evidence with peer-reviewed research published through April 2026, with particular emphasis on advances since the 2021 framework. It further considers how chronic stress, developmental trauma, and attachment disruption may shape treatment resistance and influence response across major depressive disorder, posttraumatic stress disorder, suicidality, and related refractory conditions; these developmental and relational factors are conceptualized as cross-cutting substrates of treatment resistance rather than as a sixth mechanism of ketamine action. By aligning ketamine’s biological and experiential effects with therapeutic context, psychotherapy, and structured integration, the proposed framework offers a clinically interpretable perspective to inform future research and support more individualized, durable, and mechanism-aligned approaches to treatment. The review also addresses ketamine’s medical, psychiatric, and contextual risks, arguing that safety considerations are integral to mechanism-aligned care. The framework is intended to generate testable predictions regarding patient selection, treatment timing, and durability of response, supporting future controlled evaluation.
Zitieren
APA
Muscat, S., & Hartelius, G. (2026). Mechanism-aligned ketamine therapy for treatment-resistant depression: a 2026 update—toward an integrative mechanistic framework for clinical translation. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1966279
Vancouver
Muscat S, Hartelius G. Mechanism-aligned ketamine therapy for treatment-resistant depression: a 2026 update—toward an integrative mechanistic framework for clinical translation. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1966279
BibTeX
@article{Muscat2026,
author = {Muscat, Sherry-Anne and Hartelius, Glenn},
title = {Mechanism-aligned ketamine therapy for treatment-resistant depression: a 2026 update—toward an integrative mechanistic framework for clinical translation},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1966279}
}
EUVIMED